DISPOSITION OF CLOZAPINE AND DESMETHYLCLOZAPINE IN SCHIZOPHRENIC-PATIENTS

被引：34
|
作者：
LIN, SK
CHANG, WH
CHUNG, MC
LAM, YWF
JANN, MW
机构：
[1] TAIPEI CITY PSYCHIAT CTR,BIOL PSYCHIAT LAB,TAIPEI 10510,TAIWAN
[2] UNIV TEXAS,HLTH SCI CTR,DEPT PHARMACOL,DIV CLIN PHARM,SAN ANTONIO,TX 78284
[3] UNIV TEXAS,COLL PHARM,AUSTIN,TX 78712
[4] MERCER UNIV,DEPT PHARM PRACTICE,ATLANTA,GA
[5] MERCER UNIV,DEPT PHARMACEUT SCI,ATLANTA,GA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 1994年 / 34卷 / 04期
关键词：
D O I：
10.1002/j.1552-4604.1994.tb02000.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The disposition of the atypical clozapine and its desmethyl metabolite were evaluated in fourteen male chronic patients. A single 100 mg dose of clozapine was administered and blood sampling performed over the following 72 hours. The mean (SD) oral clearance and half-life of clozapine were 55.4 (29.7) L/hr and 13.7 (9.9) hours, respectively. The mean (SD) AUC for clozapine and desmethylclozapine was 2389.9 (1406) and 751.1 (622.9) ng.hr/mL, respectively. The elimination of the metabolite is rate limited by its formation from cloza-pine. A wide interpatient variability in clozapine and desmethylclozapine pharmacokinetics was observed.
引用
收藏
页码：318 / 324
页数：7
相关论文
共 50 条
  • [41] DYSTONIA IN SCHIZOPHRENIC-PATIENTS
    DOMINGUEZ, LAN
    LAZARO, CP
    FOLIA NEUROPSIQUIATRICA, 1994, 29 (01): : 27 - 34
  • [42] THERAPY WITH SCHIZOPHRENIC-PATIENTS
    ALGER, I
    AMERICAN JOURNAL OF ORTHOPSYCHIATRY, 1960, 30 (03) : 521 - 527
  • [43] SPEECH IN SCHIZOPHRENIC-PATIENTS
    SILVERMAN, G
    MARCUS, V
    BRITISH JOURNAL OF PSYCHIATRY, 1975, 127 (OCT) : 415 - 416
  • [44] AFTERCARE IN SCHIZOPHRENIC-PATIENTS
    RIEDELL, H
    PSYCHOTHERAPIE MEDIZINISCHE PSYCHOLOGIE, 1980, 30 (01) : 22 - 35
  • [45] SHOULD CHRONIC TREATMENT-REFRACTORY AKATHISIA BE AN INDICATION FOR THE USE OF CLOZAPINE IN SCHIZOPHRENIC-PATIENTS
    LEVIN, H
    CHENGAPPA, KNR
    KAMBHAMPATI, RK
    MAHDAVI, N
    GANGULI, R
    JOURNAL OF CLINICAL PSYCHIATRY, 1992, 53 (07) : 248 - 251
  • [46] P50 AUDITORY GATING IN SCHIZOPHRENIC-PATIENTS - DIFFERING EFFECTS OF CLOZAPINE AND RISPERIDONE
    ADLER, LE
    NAGAMOTO, HT
    MCRAE, KA
    ROSS, R
    GAWTHRA, E
    GRIFFITH, J
    HOFFER, L
    FREEDMAN, RF
    SCHIZOPHRENIA RESEARCH, 1995, 15 (1-2) : 173 - 173
  • [47] DOPAMINE-D(4) RECEPTOR POLYMORPHISM IN CLOZAPINE-TREATED SCHIZOPHRENIC-PATIENTS
    KERWIN, R
    SHAIKH, S
    COLLIER, D
    GILL, M
    PILOWSKY, L
    XU, WL
    EMSON, P
    THORNTON, A
    BRITISH JOURNAL OF PHARMACOLOGY, 1993, 109 : P51 - P51
  • [48] THE USE OF CLOZAPINE IN BORDERLINE-INTELLECTUAL FUNCTIONING AND MENTALLY-RETARDED SCHIZOPHRENIC-PATIENTS
    SAJATOVIC, M
    RAMIREZ, LF
    KENNY, JT
    MELTZER, HY
    COMPREHENSIVE PSYCHIATRY, 1994, 35 (01) : 29 - 33
  • [49] STRINGENT CLOZAPINE ELIGIBILITY CRITERIA - IMPACT ON ETHNIC, GENDER, AND AGAE SUBGROUPS OF SCHIZOPHRENIC-PATIENTS
    JUAREZREYES, M
    SHUMWAY, M
    BACCHETTI, P
    BATTLE, C
    HANSEN, MS
    HARGREAVES, W
    SCHIZOPHRENIA RESEARCH, 1995, 15 (1-2) : 192 - 192
  • [50] PLASMA CLOZAPINE LEVELS AND CLINICAL-RESPONSE FOR TREATMENT-REFRACTORY SCHIZOPHRENIC-PATIENTS
    KRONIG, MH
    MUNNE, RA
    SZYMANSKI, S
    SAFFERMAN, AZ
    POLLACK, S
    COOPER, T
    KANE, JM
    LIEBERMAN, JA
    AMERICAN JOURNAL OF PSYCHIATRY, 1995, 152 (02): : 179 - 182
12345